-
Kite Pharma's Initial ZUMA Data 'Solid'; Barclays Raises Target To $65
Tuesday, September 27, 2016 - 1:38pm | 394Read More...A day after Kite Pharma Inc (NASDAQ: KITE) reported positive results from its interim analysis of ZUMA-1 for KTE-C19, which met its primary endpoint, Barclays lifted the target price from $60 to $65 on the company's shares. This implied about 18 percent upside potentials from Monday's closing price...
-
Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial
Tuesday, August 30, 2016 - 2:19pm | 314Read More...Barclays remains Overweight on Cerulean Pharma Inc (NASDAQ: CERU), despite the failure of CRLX101 in renal cancer trial, as it thinks the rationale for PARP combination is not impacted. "[T]he rationale of CRLX101's mechanism in renal cancer vs. that in combination with the high profile PARP...
-
Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'
Tuesday, July 12, 2016 - 11:28am | 432Read More...Barclays sees a potential upside of 32 percent in Alkermes Plc (NASDAQ: ALKS) shares, and subsequently raised the price target on the stock to $65 from $50. The brokerage also said the company's 2016 Vivitrol sales "could easily top guidance." "We expect a clear guidance beat and Street peak...
-
Barclays Morning Research Summary: Commodities, Comcast And Healthcare In Focus
Friday, July 8, 2016 - 1:35pm | 338Read More...Barclays has downgraded Plains GP Holdings LP (NYSE: PAGP), while revising the price targets of Comcast Corporation (NASDAQ: CMCSA), Johnson & Johnson (NYSE: JNJ), Juno Therapeutics Inc (NASDAQ: JUNO) and Plains All American Pipeline, L.P. (NYSE: PAA). The brokerage has downgraded Plains GP to...
-
Barclays Initiates 2 Cellular Cancer Therapy Plays With Equal-Weight Rating
Wednesday, July 6, 2016 - 8:15am | 300Read More...Juno Therapeutics Inc (NASDAQ: JUNO) and Kite Pharma Inc (NASDAQ: KITE) could receive initial regulatory approvals for their cellular cancer therapies next year. Barclays’ Jonathan Eckard initiated coverage of both companies with Equal-Weight ratings and price targets of $48 and $58,...
-
Mirati Target Lowered From $41 To $27 By Barclays, Overweight Maintained
Monday, June 6, 2016 - 3:52pm | 273Read More...Barclays lowered its price target on Mirati Therapeutics, Inc. (NASDAQ: MRTX) as the company suffered a setback for lead drug. The expected update for Phase 1b trial for lead drug, glesatinib, in MET positive lung cancer was a clear disappointment with a response rate in Ph2 target patients...
-
Here's Why Barclays Is Bullish On Intercept Pharma
Wednesday, June 1, 2016 - 8:54am | 307Read More...Intercept Pharmaceuticals Inc’s (NASDAQ: ICPT) liver drug Ocaliva has been granted accelerated approval by the FDA. Barclays’ Jonathan Eckard maintained an Overweight rating for the company, while raising the price target from $200 to $205. The analyst commented that the NASH...
-
Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside
Thursday, February 4, 2016 - 10:15am | 358Read More...Seattle Genetics, Inc. (NASDAQ: SGEN) share are down 28 percent since January 4. Barclays’ Jonathan Eckard initiated coverage of the company with an Overweight rating and a price target of $51. Interim pipeline and platform value drivers appear to be overlooked, Eckard The focus...
-
Why Citigroup Placed An $85 Price Target On Shares Of Alkermes
Wednesday, January 14, 2015 - 3:37pm | 245Read More...Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List. On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85 from a previous $72, reflecting the belief that...
-
Citi Analyst Defends Intercept Pharmaceuticals
Wednesday, May 28, 2014 - 2:26pm | 110Read More...In a note released Wednesday, Citi analyst Jonathan Eckard says the drop in Intercept Pharmaceuticals (NASDAQ: ICPT) shares over the past couple months, due to negative emails between Intercept's Chief Medical Officer and an officer at the National Institute of Health were "overdone." Eckard...
-
UPDATE: Citigroup Reiterates on Epizyme Awaiting Further Clarity
Friday, November 15, 2013 - 9:12am | 121Read More...In a report published Friday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Epizyme (NASDAQ: EPZM), but lowered the price target from $42.00 to $32.00. In the report, Citigroup noted, “We remain supportive of EPZM, while understanding of the initial stock reaction to early data from...
-
UPDATE: Citigroup Upgrades Amarin on Valuation
Friday, November 8, 2013 - 10:31am | 166Read More...In a report published Friday, Citigroup analyst Jonathan Eckard upgraded the rating on Amarin (NASDAQ: AMRN) from Neutral to Buy, and reiterated the $2.50 price target. In the report, Citigroup noted, “We are upgrading AMRN to Buy on valuation, maintaining our TP of $2.50. While we still see a...
-
UPDATE: Citigroup Upgrades Onconova Therapeutics on Favorable Risk-Reward
Tuesday, October 29, 2013 - 10:59am | 140Read More...In a report published Tuesday, Citigroup analyst Jonathan Eckard upgraded the rating on Onconova Therapeutics (NASDAQ: ONTX) from Neutral to Buy, but lowered the price target from $30.00 to $27.00. In the report, Citigroup noted, “We are upgrading ONTX to Buy from Neutral, viewing the recent...
-
UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities
Thursday, October 17, 2013 - 9:26am | 126Read More...In a report published Thursday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Alkermes PLC (NASDAQ: ALKS), and raised the price target from $38.00 to $43.00. In the report, Citigroup noted, “We are adding ALKS to the Citi Focus List and increasing our target price on ALKS to $43...
-
UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate
Wednesday, September 18, 2013 - 11:06am | 137Read More...In a report published Wednesday, Citigroup analyst Jonathan Eckard downgraded the rating on ArQule (NASDAQ: ARQL) from Buy to Neutral, and lowered the price target from $5.00 to $2.25. In the report, Citigroup noted, “We are changing our rating on ARQL to Neutral from Buy reflecting the increased...
